Latest News for: fda

Edit

FDA Approves Cancer Drugs for Head and Neck, Pancreatic Cancers

Chosun Ilbo 12 Nov 2026
Food and Drug Administration (FDA) announced on November 5 that it granted accelerated approval to Johnson & Johnson (J&J)’s cancer drug ‘Rybrevant Paspro’ as a treatment for head and neck cancer.
Edit

HanAll BioPharma's Imeroprubart Succeeds in Phase 2b, Faces FDA Hurdles

Chosun Ilbo 12 Nov 2026
However, many challenges remain ... Its U.S ... It was conducted in two phases ... ◇“Consulting FDA on approval path”…other indications also variables ... Food and Drug Administration (FDA) and subsequent trial plans by early next year at the latest ... .
Edit

Taking Ozempic or Zepbound? FDA orders warning about rare vision loss risk

Hastings Tribune 11 Nov 2026
The Food and Drug Administration is requiring new warnings on GLP-1 drugs, including Ozempic, Wegovy and Zepbound, about a potential increased risk of a rare eye condition that can cause permanent vision loss ... .
Edit

FDA approves new stroke drug after 26% drop in recurrent events

Ynet 11 Nov 2026
Bayer’s once-daily Sunharbo becomes the ...
Edit

GLP-1 drugs to carry warning about rare vision-loss side effect, FDA says

CBS News 11 Nov 2026
GLP-1 drugs will now carry a warning for a rare, but potentially dangerous side effect that can lead to vision loss, the FDA says. Dr. Rachel Pessah-Pollack joins CBS News to discuss ... .
Edit

FDA adds rare vision-loss warning to popular GLP-1 drugs

The Sun Chronicle 11 Nov 2026
WASHINGTON — Popular weight loss drugs including Ozempic and Wegovy will carry a new warning about a possible rare side effect that can sometimes lead to permanent vision loss, U.S. health regulators announced Monday ... .
Edit

Bayer wins US FDA approval for Sunharbo to reduce repeat strokes

Emirates 24/7 11 Nov 2026
⁠Current big-selling blood-clot preventers, such as Pfizer and Bristol Myers Squibb's Eliquis and Xarelto, sold by Johnson & Johnson and Bayer, work by blocking Factor Xa, a different protein involved in the formation of blood clots ... .
Edit

NeOnc Technologies Granted FDA Type B End-of-Phase Meeting to Discuss Potential Accelerated Approval Pathway and ...

The Daily Record - Dunn 11 Nov 2026
CALABASAS, Calif., Nov. 11, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq. NTHI) (“NeOnc” or the ....
×